ASELIZUMAB: A DETAILED INVESTIGATION INTO HUDREG-55

Aselizumab, referred to as HuDreg-55, signifies a innovative monoclonal antibody engineered to bind to the complement system . How it works involves interfering with the traditional complement pathway, likely providing efficacy in a range of inflammatory diseases . Preclinical studies suggest its